👀 Spotlight on Myelofibrosis 2024: The Critical Evolution of JAK Inhibitors – UC Irvine – Angela Fleischman, MD
Angela Fleischman, MD – UC Irvine delves into the latest advancements in myelofibrosis treatment, particularly focusing on the role of JAK inhibitors and the emerging potential of gene therapy as of 2024. It emphasizes the critical need for specialized care in non-malignant hematology clinics and the promising future of personalized treatment strategies for myelofibrosis patients. Dr. Zahra Pakbaz’s exploration of the American Society of Hematology meeting emphasized the vital role of Non-Malignant